F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer - The New York Times
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times
The health section covers stories about medical progress, recovery, and wellbeing. We look for genuine advances: new therapies clearing regulatory hurdles, diseases being eradicated in specific regions, communities improving public health outcomes through evidence-based programs. Celebrity wellness trends and supplement marketing do not make the cut.
The morning letter delivers the day's best positive headlines before the rest of the internet gets loud. Free, no tracking, one click to leave.
Get the morning letter →
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
The approach focuses on the patient priorities, seeing the same clinicians, and involving people close to them.
Without brain surgery guided by live AI assistance, Rhys Hibbert could have lost his sight to a tumour.
Over the next year, nearly four million will receive invites on the NHS App or via text message, email or letter to orde…
Most news feeds won't give you another one. Our morning letter will: one email at sunrise with the day's best good news.
Start tomorrow morning →